Novel agents for castration-resistant prostate cancer: Early experience and beyond

International Journal of Urology

Volumn 23, Issue 2, 2016, Pages 114-121

  Fujimoto, Naohiro ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Castration resistance; Future progress; Novel agents; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; CABAZITAXEL; ENZALUTAMIDE; ANTINEOPLASTIC AGENT; RADIUM; RADIUM-223; TAXOID;

ANDROGEN SYNTHESIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL TRIAL (TOPIC); CROSS RESISTANCE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; MALE; PROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; HUMANS; MALE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIUM; TAXOIDS;

EID: 84940484592     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12907     Document Type: Review

References (79)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502-12.
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004; 351: 1513-20.
3. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 2011; 364: 1995-2005.
4. Ryan CJ, Smith MR, Fizazi K et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015; 16: 152-60.
5. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 2012; 367: 1187-97.
6. Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 2014; 371: 424-33.
7. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010; 363: 411-22.
8. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54.
9. Parker C, Nilsson S, Heinrich D et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 2013; 369: 213-23.
10. Tilki D, Evans CP. The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions. Can. J. Urol. 2014;21(2 Supp 1:7-13.
11. Wyatt AW, Gleave ME. Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol. Med. 2015; doi: 10.15252/emmm.201303701.
12. Katsogiannou M, Ziouziou H, Karaki S, Andrieu C, Henry de Villeneuve M, Rocchi P. The hallmarks of castration-resistant prostate cancers. Cancer Treat. Rev. 2015; doi: 10.1016/j.ctrv.2015.05.003.
13. Knuuttila M, Yatkin E, Kallio J et al. Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. Am. J. Pathol. 2014; 184: 2163-73.
14. Fujimoto N, Kubo T, Inatomi H et al. Polymorphisms of the androgen transporting gene SLCO2B1 may influence the castration resistance of prostate cancer and the racial differences in response to androgen deprivation. Prostate Cancer Prostatic Dis. 2013; 16: 336-40.
15. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008; 68: 4447-54.
16. Locke JA, Guns ES, Lubik AA et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008; 68: 6407-15.
17. Ryan CJ, Crawford D, Shore ND et al. Effect of abiraterone acetate and low-dose prednisone on PSA in patients with nonmetastatic castration-resistant prostate cancer: the results from IMAAGEN core study. J. Clin. Oncol. 2014; 32 (Suppl 5): abstr 5086.
18. Li Z, Bishop AC, Alyamani M et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 2015; doi: 10.1038/nature14406.
19. Fizazi K, Scher HI, Molina A et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012; 13: 983-92.
20. Burgio SL, Conteduca V, Rudnas B et al. PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer. Clin. Genitourin Cancer 2015; 13: 39-43.
21. Narmala SK, Boulmay BC. PSA flare after initiation of abiraterone acetate. J. Community Support Oncol. 2014; 12: 191-2.
22. Azad AA, Eigl BJ. Evaluation of prostate-specific antigen response following cessation of abiraterone acetate: is there evidence for a withdrawal syndrome? Eur. Urol. 2014; 65: 504-5.
23. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-90.
24. Efstathiou E, Titus M, Wen S et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur. Urol. 2015; 67: 53-60.
25. Fizazi K, Scher HI, Miller K et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 2014; 15: 1147-56.
26. Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des. Devel. Ther. 2011; 5: 117-24.
27. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann. Oncol. 2013; 24: 1802-7.
28. Loriot Y, Bianchini D, Ileana E et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann. Oncol. 2013; 24: 1807-12.
29. Pezaro CJ, Omlin AG, Altavilla A et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents. Eur. Urol. 2014; 66: 459-65.
30. Schrader AJ, Boegemann M, Ohlmann CH et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur. Urol. 2014; 65: 30-6.
31. Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate 2014; 74: 1278-85.
32. Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur. Urol. 2015; 67: 23-9.
33. Cheng HH, Gulati R, Azad A et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis. 2015; 18: 122-7.
34. Thomsen FB, Roder MA, Rathenborg P, Brasso K, Borre M, Iversen P. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand. J. Urol. 2014; 48: 268-75.
35. Schmid SC, Geith A, Boker A et al. Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer. Adv. Ther. 2014; 31: 234-41.
36. Badrising S, van der Noort V, van Oort IM et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014; 120: 968-75.
37. Mezynski J, Pezaro C, Bianchini D et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann. Oncol. 2012; 23: 2943-7.
38. Pezaro CJ, Moulec SL, Albiges L et al. Response to cabazitaxel in CRPC patients previously treated with docetaxel and abiraterone acetate. J. Clin. Oncol. 2013; 31 (Suppl 6): abstr 155.
39. Nelson PS. Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J. Clin. Oncol. 2012; 30: 644-6.
40. Dehm SM, Tindall DJ. Alternatively spliced androgen receptor variants. Endocr. Relat. Cancer 2011; 18: R183-96.
41. Small EJ, Youngren J, Thomas G et al. Androgen receptor (AR) amplification in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to therapy with abiraterone acetate or enzalutamide: preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). J. Clin. Oncol. 2014; 32 (Suppl 5): abstr 5020.
42. Chang KH, Li R, Kuri B et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 2013; 154: 1074-84.
43. Cai C, Chen S, Ng P et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011; 71: 6503-13.
44. van de Wijngaart DJ, Molier M, Lusher SJ et al. Systematic structure-function analysis of androgen receptor Leu701 mutants explains the properties of the prostate cancer mutant L701H. J. Biol. Chem. 2010; 285: 5097-105.
45. Richards J, Lim AC, Hay CW et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012; 72: 2176-82.
46. Zhao XY, Malloy PJ, Krishnan AV et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 2000; 6: 703-6.
47. Korpal M, Korn JM, Gao X et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 2013; 3: 1030-43.
48. Joseph JD, Lu N, Qian J et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov. 2013; 3: 1020-9.
49. Arora VK, Schenkein E, Murali R et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309-22.
50. Matsumoto H, Yamamoto Y, Shiota M et al. Cotargeting androgen receptor and clusterin delays castrate-resistant prostate cancer progression by inhibiting adaptive stress response and AR stability. Cancer Res. 2013; 73: 5206-17.
51. Shiota M, Yokomizo A, Takeuchi A et al. Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer. Clin. Cancer Res. 2014; 20: 951-61.
52. Shiota M, Bishop JL, Takeuchi A et al. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Oncotarget 2015; 6: 9086-98.
53. Carver BS, Chapinski C, Wongvipat J et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011; 19: 575-86.
54. Haile S, Sadar MD. Androgen receptor and its splice variants in prostate cancer. Cell. Mol. Life Sci. 2011; 68: 3971-81.
55. Hu R, Lu C, Mostaghel EA et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012; 72: 3457-62.
56. Guo Z, Yang X, Sun F et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009; 69: 2305-13.
57. Antonarakis ES, Lu C, Wang H et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 2014; 371: 1028-38.
58. Thadani-Mulero M, Portella L, Sun S et al. Androgen receptor splice variants determine taxane sensitivity in prostate cancer. Cancer Res. 2014; 74: 2270-82.
59. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM. Kyprianou N Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 2010; 70: 7992-8002.
60. Antonarakis ES, Lu C, Chen Y et al. AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 2015; 33 (Suppl 7): abstr 138.
61. van Soest RJ, van Royen ME, de Morree ES et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur. J. Cancer 2013; 49: 3821-30.
62. Soifer HS, Souleimanian N, Wu S et al. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J. Biol. Chem. 2012; 287: 3777-87.
63. Nadal R, Zhang Z, Rahman H et al. Clinical activity of enzalutamide in Docetaxel-naive and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer. Prostate 2014; 74: 1560-8.
64. Schweizer MT, Zhou XC, Wang H et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer. Eur. Urol. 2014; 66: 646-52.
65. Angelergues A, Maillet D, Flechon A et al. Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 2014; 32 (Suppl 4): abstr 282.
66. Leibowitz-Amit R, Templeton AJ, Omlin A et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann. Oncol. 2014; 25: 657-62.
67. Xia S, Kohli M, Du M et al. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer. Oncotarget 2015; 6: 16411-21.
68. Azad AA, Volik SV, Wyatt AW et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin. Cancer Res. 2015; 21: 2315-24.
69. Salvi S, Casadio V, Conteduca V et al. Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. Br. J. Cancer 2015; 112: 1717-24.
70. Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012; 72: 1494-503.
71. Rathkopf DE, Antonarakis ES, Shore ND et al. ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 2013; 31 (Suppl 6): abstr 48.
72. Fizazi K, Massard C, Bono P et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol. 2014; 15: 975-85.
73. Brand LJ, Olson ME, Ravindranathan P et al. EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer. Oncotarget 2015; 6: 3811-24.
74. Montgomery RB, Antonarakis ES, Hussain M et al. A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone. J. Clin. Oncol. 2015; 33 (Suppl): abstr TPS5072.
75. Njar VC, Brodie AM. Discovery and development of Galeterone (TOK-001 or VN/124-1) for the treatment of all stages of prostate cancer. J. Med. Chem. 2015; 58: 2077-87.
76. Efstathiou E, Titus MA, Wen S et al. Enzalutamide (ENZA) in combination with abiraterone acetate (AA) in bone metastatic castration resistant prostate cancer (mCRPC). J. Clin. Oncol. 2014; 32 (Suppl): abstr 5000.
77. Taplin ME, Manola J, Oh WK et al. A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones. BJU Int. 2008; 101: 1084-9.
78. Minato A, Fujimoto N, Kubo T, Harada S, Akasaka S, Matsumoto T. Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer. Med. Oncol. 2012; 29: 2895-900.
79. Venkitaraman R, Lorente D, Murthy V et al. A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur. Urol. 2015; 67: 673-9.